Peripheral Arterial Disease Trial, Recruiting NCT06480786 Sponsor: University of Nebraska Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT06480786
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 19 and 89 years old
  • People who have been diagnosed with diabetes
  • People who have signs or symptoms of nerve damage (neuropathy), with a pain score of 5 or higher on a pain scale, and have been diagnosed with poor blood flow in the legs (peripheral arterial disease), causing leg pain with walking that scores 6 or higher on a pain scale, lasting at least 3 months
  • People who have already had a successful temporary spinal cord stimulator (SCS) trial — meaning it reduced their chronic leg pain by more than 50% — and are scheduled to have a permanent SCS device implanted before the study begins

Who may not be able to join:

  • People with a psychological or psychiatric condition that is not well managed
  • People who are unable to temporarily stop blood-thinning medications according to specific medical guidelines (confirm with trial site)
  • People who have wounds that are not healing
  • People who have gangrene (tissue death due to lack of blood supply)
  • People who have severely reduced blood flow to a limb that is threatening tissue survival (critical limb ischemia)
  • People who have previously had a lower leg or foot amputation
  • People who would be unable to attend or complete the required follow-up visits
  • People whose spine is found to be unstable based on specific spinal X-rays
  • People who currently have or have previously had a spinal cord stimulator implant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Pellegrino, MD, University of Nebraska

Phone: 402-552-3077

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Nebraska
Registry
ClinicalTrials.gov
Start date
18 December 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

High-frequency Spinal Cord Stimulation Effect on Analgesia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov